id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-267260-8l831mre	Brenner, Erica J.	Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry	2020-05-18		.txt	text/plain	3136	170	43	Risk factors for severe COVID-19 among IBD patients included increasing age (adjusted odds ratio [aOR] 1.04, 95% CI 1.01-1.02), ≥2 comorbidities (aOR 2.9, 95% CI 1.1-7.8), systemic corticosteroids (aOR 6.9, 95% CI 2.3-20.5), and sulfasalazine or 5-aminosalicylate use (aOR 3.1, 95% CI 1.3-7.7). To understand the impact of IBD on case fatality, we computed expected and observed deaths and age-standardized mortality ratios (SMR) utilizing published agestratified COVID-19 case fatality rates from China and Italy 2, 23 and publically available data from the U.S. 24, 25 Multivariable logistic regression estimated the independent effects of age, sex, disease (CD vs UC/IBD-U), disease activity, smoking, BMI ≥30, and number of comorbidities (0, 1, ≥2) on the primary outcome of severe COVID-19, defined as a composite of ICU admission, ventilator use, and/or death, consistent with existing COVID-19 literature. In our exploratory analyses, we found that TNF antagonist combination therapy, compared to monotherapy, was positively associated with the outcome of hospitalization or death (aOR 5.0, 95% CI 2.0-12.3), after adjusting for clinical and demographic variables and use of systemic corticosteroids and 5-ASA/sulfasalazine.	./cache/cord-267260-8l831mre.txt	./txt/cord-267260-8l831mre.txt